Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/4835 |
Resumo: | Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice. |
id |
RCAP_5108f7f3d17e0023c76931db441adf31 |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/4835 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert GroupHCC ENDHumansCardiovascular Diseases* / drug therapyCardiovascular Diseases* / epidemiologyDiabetes Mellitus, Type 2* / diagnosisDiabetes Mellitus, Type 2* / drug therapyDiabetes Mellitus, Type 2* / epidemiologyGlucagon-Like Peptide 1 / metabolismGlucagon-Like Peptide-1 Receptor / agonistsHypoglycemic Agents / pharmacologyHypoglycemic Agents / therapeutic useLiraglutide / pharmacologyLiraglutide / therapeutic useGlucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice.ElsevierRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEJanez, AMuzurovic, EStoian, AHaluzik, MGuja, CCzupryniak, LDuvnjak, LLalic, NTankova, TBogdanski, PPapanas, NSilva Nunes, JKempler, PFras, ZRizzo, M2024-03-08T16:28:46Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4835engInt J Cardiol . 2022 Oct 15:365:8-18.10.1016/j.ijcard.2022.07.017info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-10T06:26:20Zoai:repositorio.chlc.min-saude.pt:10400.17/4835Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:14:23.066899Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
title |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
spellingShingle |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group Janez, A HCC END Humans Cardiovascular Diseases* / drug therapy Cardiovascular Diseases* / epidemiology Diabetes Mellitus, Type 2* / diagnosis Diabetes Mellitus, Type 2* / drug therapy Diabetes Mellitus, Type 2* / epidemiology Glucagon-Like Peptide 1 / metabolism Glucagon-Like Peptide-1 Receptor / agonists Hypoglycemic Agents / pharmacology Hypoglycemic Agents / therapeutic use Liraglutide / pharmacology Liraglutide / therapeutic use |
title_short |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
title_full |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
title_fullStr |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
title_full_unstemmed |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
title_sort |
Translating Results From the Cardiovascular Outcomes Trials with Glucagon-Like Peptide-1 Receptor Agonists Into Clinical Practice: Recommendations From a Eastern and Southern Europe Diabetes Expert Group |
author |
Janez, A |
author_facet |
Janez, A Muzurovic, E Stoian, A Haluzik, M Guja, C Czupryniak, L Duvnjak, L Lalic, N Tankova, T Bogdanski, P Papanas, N Silva Nunes, J Kempler, P Fras, Z Rizzo, M |
author_role |
author |
author2 |
Muzurovic, E Stoian, A Haluzik, M Guja, C Czupryniak, L Duvnjak, L Lalic, N Tankova, T Bogdanski, P Papanas, N Silva Nunes, J Kempler, P Fras, Z Rizzo, M |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Janez, A Muzurovic, E Stoian, A Haluzik, M Guja, C Czupryniak, L Duvnjak, L Lalic, N Tankova, T Bogdanski, P Papanas, N Silva Nunes, J Kempler, P Fras, Z Rizzo, M |
dc.subject.por.fl_str_mv |
HCC END Humans Cardiovascular Diseases* / drug therapy Cardiovascular Diseases* / epidemiology Diabetes Mellitus, Type 2* / diagnosis Diabetes Mellitus, Type 2* / drug therapy Diabetes Mellitus, Type 2* / epidemiology Glucagon-Like Peptide 1 / metabolism Glucagon-Like Peptide-1 Receptor / agonists Hypoglycemic Agents / pharmacology Hypoglycemic Agents / therapeutic use Liraglutide / pharmacology Liraglutide / therapeutic use |
topic |
HCC END Humans Cardiovascular Diseases* / drug therapy Cardiovascular Diseases* / epidemiology Diabetes Mellitus, Type 2* / diagnosis Diabetes Mellitus, Type 2* / drug therapy Diabetes Mellitus, Type 2* / epidemiology Glucagon-Like Peptide 1 / metabolism Glucagon-Like Peptide-1 Receptor / agonists Hypoglycemic Agents / pharmacology Hypoglycemic Agents / therapeutic use Liraglutide / pharmacology Liraglutide / therapeutic use |
description |
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have occurred. This document from a Eastern and Southern European Diabetes Expert Group discusses the results of GLP-1 RA CV outcomes trials, their impact on recent clinical guidelines for the management of T2DM, and some selected combination regimens utilising GLP-1 RAs. We also propose an algorithm for guiding GLP-1 RA-based treatment according to patients' characteristics, which can be easily applied in every day clinical practice. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022 2022-01-01T00:00:00Z 2024-03-08T16:28:46Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/4835 |
url |
http://hdl.handle.net/10400.17/4835 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Int J Cardiol . 2022 Oct 15:365:8-18. 10.1016/j.ijcard.2022.07.017 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137796947968000 |